Newest Content

Filter
You Filtered On: John McCamant
Keyword Image
John McCamant: Investing in Biotech
06/04/2018 3:45 pm EST

At MoneyShow, John McCamant on investing in biotech. We recommend diversification. Second or third t...

McCamant, John Image
McCamant, John
Duration: 7:51
Keyword Image
Pipeline Progress at Ionis
04/02/2018 5:00 am EST

Ionis Pharmaceuticals (IONS) recently reported its fourth quarter 2017 results with strong Spinraza ...

John McCamant Image
John McCamant
Tickers: IONS
Keyword Image
Picking Biotech Stocks in the Trump Era
02/14/2018 12:00 am EST

After a three-year bull market and year-and-a-half bear market in biotech stocks, 2017 had seen the ...

McCamant, John Image
McCamant, John
Duration: 49:40
Keyword Image
Alkermes and the Opioid Crisis
02/02/2018 5:00 am EST

After a rather quiet year in 2017, Alkermes (ALKS) is due for major clinical, regulatory and commerc...

John McCamant Image
John McCamant
Tickers: BIIB
Keyword Image
Madrigal: Best in Class in NASH?
10/13/2017 5:00 am EST

We recently held a conference call with the management team at Madrigal (MDGL) and came away even mo...

John McCamant Image
John McCamant
Tickers: MDGL
Keyword Image
John McCamant on Anti-Cancer Therapies
09/22/2017 12:17 pm EST

At MoneyShow San Francisco, John McCamant outlines several anti-cancer drug makers and possible bre...

McCamant, John Image
McCamant, John
Duration: 3:29
Keyword Image
Nektar: "A Slew of Good News"
08/10/2017 2:54 am EST

Nektar Therapeutics (NKTR) reported positive top-line Human Abuse Liability (HAL) data for NKTR-181,...

John McCamant Image
John McCamant
Tickers: NKTR